Provided by Tiger Fintech (Singapore) Pte. Ltd.

AstraZeneca PLC

76.68
-0.8199-1.06%
Volume:3.07M
Turnover:235.03M
Market Cap:237.80B
PE:34.08
High:76.97
Open:76.11
Low:76.11
Close:77.50
Loading ...

Ionis Pharmaceuticals Says Transthyretin-Mediated Amyloidosis Treatment Gets Approval in Europe

MT Newswires Live
·
Yesterday

3 Top Cancer Biotechs to Keep An Eye On in 2025

Zacks
·
07 Mar

Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint

MT Newswires Live
·
07 Mar

AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients

Benzinga
·
07 Mar

AstraZeneca announces MATTERHORN trial results

TIPRANKS
·
07 Mar

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

Business Wire
·
07 Mar

AstraZeneca’s MATTERHORN Phase III trial showed improvement in endpoint of EFS

TIPRANKS
·
07 Mar

Astrazeneca (AZN) Stock Moves -0.63%: What You Should Know

Zacks
·
07 Mar

Inside The Quantum Computing Crash Triggered By Nvidia CEO — And What His Upcoming 'Quantum Day' May Bring

Blockhead
·
06 Mar

Is AstraZeneca PLC (LON:AZN) Trading At A 45% Discount?

Simply Wall St.
·
06 Mar

AstraZeneca PLC Stock Falls Wednesday, Underperforms Market

Dow Jones
·
06 Mar

Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com
·
05 Mar

AstraZeneca PLC ADR Outperforms Competitors On Strong Trading Day

Dow Jones
·
05 Mar

AstraZeneca (AZN) Receives a Buy from Bernstein

TIPRANKS
·
04 Mar

AstraZeneca PLC Stock Falls Monday, Underperforms Market

Dow Jones
·
04 Mar

Astrazeneca-Amgen Asthma Treatment Reduces Nasal Polyps, Surgery Rates in Phase III Trial

MT Newswires Live
·
03 Mar